Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Cutaneous Squamous Cell Carcinoma × Doxorubicin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 20 Breast Neoplasms 17 Lymphoma 12 Sarcoma 11 Lymphoma, Non-Hodgkin 9 Lymphoma, B-Cell 7 Lymphoma, Follicular 6 Hodgkin Disease 6 Lymphoma, Mantle-Cell 5 Immunoblastic Lymphadenopathy 5 Ovarian Neoplasms 4 Neoplasms 4 Lymphoma, Large-Cell, Anaplastic 4 Leukemia, Lymphocytic, Chronic, B-Cell 4 Carcinoma, Hepatocellular 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Multiple Myeloma 3 Lymphoma, T-Cell, Peripheral 3 Lymphoma, Primary Effusion 3 Chondrosarcoma 3 Triple Negative Breast Neoplasms 2 Solitary Fibrous Tumors 2 Sarcoma, Clear Cell 2 Recurrence 2 Plasmablastic Lymphoma 2 Osteosarcoma 2 Neoplasm Metastasis 2 Lymphoma, T-Cell 2 Lymphoma, B-Cell, Marginal Zone 2 Liver Neoplasms 2

Interventions

cemiplimab 1 Transdermal Patch 1 Sirolimus 1 Prednisone 1 Everolimus 1 Doxorubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05377905 2025-04-11

cSCC

University of Pittsburgh

Phase 1/2 Recruiting

Cutaneous Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡